Lupin Q2FY26 Earnings: U.S. Growth on Track for $1B+ Sales, Margins at 26% & Profit Grows 73% YoY #ETNOW
Lupin Q2FY26 Earnings: U.S. Growth on Track for $1B+ Sales, Margins at 26% & Profit Grows 73% YoY
Lupin Q2FY26 Earnings: U.S. Growth on Track for $1B+ Sales, Margins at 26% & Profit Grows 73% YoY
Lupin delivers a strong Q2 led by robust U.S. growth from Tolvaptan, Mirabegron, and Spiriva. CEO Vinita Gupta confirms Lupin remains on track for $1B+ U.S. sales and sustained margin expansion. CFO Ramesh Swaminathan guides for 26% margins in FY26, while MD Nilesh Gupta highlights solid India growth in cardio, respiratory, and diabetes segments. Watch this ET Now exclusive for details on EMEA growth, upcoming biosimilars, and key injectable launches like Risperdal Consta and Liraglutide.
#etnow #lupinshare #q2earnings #q2results #lupin #businessnews #stockmarket #topnews
YouTube Channel – https://www.youtube.com/@ETNow
Subscribe To ET Now For Latest Updates On Stocks Market News , Business News, Company News, IPO & More | https://bit.ly/SubscribeToETNow
Subscribe Now To Our Network Channels :-
ET Now Swadesh: https://www.youtube.com/etnowswadesh
Times Now: http://goo.gl/U9ibPb
Social Media Links :-
Twitter – http://goo.gl/hA0vDt
Facebook – http://goo.gl/5Lr4mC
Website – https://ift.tt/po3ymB8
Follow us on Google News for latest updates
ET Now: https://ift.tt/w2K5uMd
Times Now Navbharat: https://bit.ly/3zDaKJo
Times Now : https://bit.ly/3CyrrYg
Zoom: https://bit.ly/3CEK0dv
Thank you for your support in keeping this website running.💛
View on “Tokyo Trend News”
コメントを送信